Skip to content

IVF/ICSI Protocols in Poor Responders With Growth Hormone

Which is the Best IVF/ICSI Protocol to be Used in Poor Responders Receiving Growth Hormone as an Adjuvant Treatment ? A Prospective Randomized Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01897324
Enrollment
287
Registered
2013-07-11
Start date
2013-07-31
Completion date
2015-01-31
Last updated
2015-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility Due to Diminished Ovarian Reserve

Keywords

Poor Ovarian Response, Poor Responders, IVF/ICSI, Growth Hormone

Brief summary

in this study, we are trying to monitor the effect of the addition of growth hormone on the different down regulation protocols ( long, short, antagonist and microflare). The outcome will be primarily assessed by the clinical pregnancy rates.

Detailed description

Poor responders undergoing IVF/ICSI cycles have emerged as a major problem. the need to find a proper stimulation protocol is a must. in this study we are trying to detect the best stimulation protocol ,in addition to growth hormone ,that can give the highest pregnancy rates in these patients.

Interventions

Sponsors

Woman's Health University Hospital, Egypt
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

ESHRE consensus 2011,At least two of the following three features must be present: * Advanced maternal age (≥40 years) or any other risk factor for POR; * A previous POR (≤3 oocytes with a conventional stimulation protocol); * An abnormal ovarian reserve test (i.e. AFC \< 5-7 follicles or AMH \< 0.5 -1.1 ng/ml).

Exclusion criteria

* female patients with causes of infertility other than poor ovarian reserve * females suffering from congenital or acquired uterine anomalies * females with focal uterine lesions * females who had previous ovarian surgeries * females with history of previous exposure to radiotherapy , or chemotherapy * females refusing to get enrolled in the study

Design outcomes

Primary

MeasureTime frameDescription
Numbers of oocytes retrieved and number of fertilized oocytes2 yearsNumber of oocytes retrieved on the day of vaginal egg collection guided by trans vaginal ultrasound scan , 35 hours after hCG administration.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026